McKesson acquires controlling interest in Core Ventures
By HME News Staff
Updated 9:28 AM CDT, Wed August 28, 2024
IRVING, Texas – McKesson Corp. has signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures (Core Ventures) for approximately $2.49 billion in cash. Core Ventures is a business and administrative services organization established by the Florida Cancer Specialists & Research Institute, a physician-owned community oncology practice. “This milestone marks an important step forward in our efforts to advance community-based oncology care,” said Brian Tyler, CEO, McKesson. “By growing our Oncology platform, we will bring advanced treatments and improved care experiences to patients, while also reducing the overall cost of care. FCS and Core Ventures’ expertise and patient-first approach align with our commitment to accelerating clinical development, improving patient outcomes, and expanding access to quality cancer care in the community. We are also pleased to welcome Florida Cancer Specialists & Research Institute to The US Oncology Network, reinforcing our dedication to empowering community-based providers to independently thrive in today’s rapidly evolving healthcare landscape.” FCS physicians will continue to retain a minority interest in Core Ventures. McKesson’s controlling will represent approximately 70% ownership. Following completion of the transaction, Core Ventures will be part of the Oncology platform and its financial results will be reported within McKesson’s US Pharmaceutical segment.
Comments